| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | CCN1; CCNA |
| WB Predicted band size | 49 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CCNA2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是模拟生成的关于CCNA2抗体的参考文献示例(非真实文献，仅供格式参考)：
---
1. **"CCNA2 as a Prognostic Biomarker in Breast Cancer: Immunohistochemical Analysis Using a Novel Monoclonal Antibody"**
*Authors: Zhang L, et al.*
摘要：本研究开发了一种针对CCNA2蛋白的新型单克隆抗体，并验证其在乳腺癌组织中的特异性。通过免疫组化分析发现，CCNA2高表达与患者预后不良显著相关。
2. **"Development and Validation of a CCNA2-Specific Antibody for Flow Cytometry Applications"**
*Authors: Smith J, Patel R.*
摘要：文章报道了一种经流式细胞术验证的高特异性CCNA2多克隆抗体的开发过程，证明其可用于细胞周期分析，尤其在同步化细胞实验中检测G2/M期标志物。
3. **"CCNA2 Antibody-Based Screening Identifies Therapeutic Vulnerabilities in Lung Adenocarcinoma"**
*Authors: Kim H, et al.*
摘要：利用CCNA2抗体进行蛋白质表达筛查，发现CCNA2过表达的肺腺癌细胞对CDK抑制剂敏感，提示其作为联合治疗靶点的潜力。
4. **"Comparative Study of Commercial CCNA2 Antibodies in Human Colorectal Cancer Tissues"**
*Authors: Müller S, et al.*
摘要：对比了五种市售CCNA2抗体的灵敏度和特异性，提出标准化检测方案以减少不同实验室间结果差异，强调抗体选择对临床病理诊断的重要性。
---
**说明**：以上文献为模拟生成，实际引用时建议通过**PubMed**或**Google Scholar**检索关键词(如“CCNA2 antibody”、“Cyclin A2 biomarker”)获取真实研究。如需文献获取指导，可进一步说明需求。
CCNA2 antibody targets Cyclin A2. a key regulatory protein involved in cell cycle progression. Cyclin A2. encoded by the CCNA2 gene, belongs to the cyclin family that partners with cyclin-dependent kinases (CDKs) to drive transitions between cell cycle phases. Specifically, Cyclin A2 interacts with CDK1 and CDK2. playing dual roles in S phase initiation (by regulating DNA replication) and G2/M phase transition (by promoting mitotic entry). Its expression peaks during S phase and persists until early mitosis, after which it undergoes proteasomal degradation.
Antibodies against CCNA2 are widely used in research to study cell cycle dynamics, cancer biology, and developmental processes. They enable detection of Cyclin A2 protein levels through techniques like Western blotting, immunofluorescence, and immunohistochemistry. Such studies have revealed that Cyclin A2 overexpression correlates with uncontrolled cell proliferation in various cancers, making it a potential diagnostic marker or therapeutic target. Conversely, its downregulation is linked to cell cycle arrest and differentiation.
Commercial CCNA2 antibodies are typically raised in hosts like rabbits or mice using immunogenic peptide sequences. Specificity is validated via knockout controls or siRNA knockdown experiments. Researchers prioritize antibodies with minimal cross-reactivity to other cyclins (e.g., Cyclin A1) to ensure accurate interpretation. These tools continue to advance understanding of cell cycle regulation and its dysregulation in diseases.
×
